From: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling
Test | Method | p (FET) | p<0.05 | robust | ||
---|---|---|---|---|---|---|
 |  |  |  | OR | p<0.1 | p<0.05 |
EGFR | CNA | 0.0008 | * | * | * | * |
PD-L1 | IHC | 0.0057 | * | * | * | * |
EGFR | NGS | 0.011 | * | * | * | Â |
PD-1 | IHC | 0.014 | * | * | * | * |
NF1 | NGS | 0.019 | * | * | * | Â |
EGFRvIII | FFA | 0.020 | * | * | * | Â |
CALR | CNA | 0.038 | * | Â | Â | Â |
IDH1 | NGS | 0.046 | * | * | Â | Â |
EGFRvIII | FA | 0.060 | Â | Â | Â | Â |
NTRK1 | F-RNA | 0.074 | Â | Â | Â | Â |
LYL1 | CNA | 0.075 | Â | Â | Â | Â |
SHP-2 | NGS | 0.0877 | Â | Â | Â | Â |
IDH2 | NGS | 0.081 | Â | Â | Â | Â |
PTCH1 | NGS | 0.081 | Â | Â | Â | Â |